.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Fuji
Cipla
Argus Health
Johnson and Johnson
Healthtrust
Cerilliant
Mallinckrodt
Express Scripts
Medtronic

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 075401

« Back to Dashboard
NDA 075401 describes TAZTIA XT, which is a drug marketed by Actavis Labs Fl Inc and is included in one NDA. It is available from two suppliers. Additional details are available on the TAZTIA XT profile page.

The generic ingredient in TAZTIA XT is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.

Summary for 075401

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 075401

Mechanism of ActionCalcium Channel Antagonists

Suppliers and Packaging for NDA: 075401

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TAZTIA XT
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL 075401 ANDA PuraCap Laboratories LLC dba Blu Pharmaceuticals 24658-341 24658-341-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (24658-341-30)
TAZTIA XT
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL 075401 ANDA PuraCap Laboratories LLC dba Blu Pharmaceuticals 24658-341 24658-341-90 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (24658-341-90)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength120MG
Approval Date:Apr 10, 2003TE:AB4RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength180MG
Approval Date:Apr 10, 2003TE:AB4RLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength240MG
Approval Date:Apr 10, 2003TE:AB4RLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fuji
Cerilliant
US Department of Justice
Chubb
Federal Trade Commission
Chinese Patent Office
Cantor Fitzgerald
Johnson and Johnson
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot